Sarcopenia Or Frailty? European, U.S. Definitions Diverge
This article was originally published in Pharmaceutical Approvals Monthly
European stakeholders are working toward “physical frailty and sarcopenia” as a geriatric indication, a broader concept than the sarcopenia definition proposed in the U.S.
You may also be interested in...
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
Two required confirmatory studies will bolster application that relied on historical controls for orphan neurodegenerative disease.
Keeping Track: Terliprez, Sotyktu Keep Up US FDA’s Novel Approvals Pace; Submissions By Pfizer, Chiesi And BioLineRx
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker